Sava Infond d.o.o. Buys Shares of 21,000 Royalty Pharma plc (NASDAQ:RPRX)

Sava Infond d.o.o. purchased a new position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 21,000 shares of the biopharmaceutical company's stock, valued at approximately $536,000.

Other large investors also recently modified their holdings of the company. Brooklyn Investment Group boosted its stake in Royalty Pharma by 1,006.9% during the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 876 shares in the last quarter. Allworth Financial LP lifted its holdings in shares of Royalty Pharma by 417.6% during the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 877 shares during the period. Riverview Trust Co boosted its position in shares of Royalty Pharma by 3,953.3% during the 4th quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 1,186 shares in the last quarter. Fifth Third Bancorp increased its stake in Royalty Pharma by 187.1% in the fourth quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock valued at $39,000 after acquiring an additional 997 shares during the period. Finally, Rakuten Securities Inc. lifted its stake in Royalty Pharma by 160.5% during the fourth quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 1,003 shares during the period. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

RPRX has been the topic of several analyst reports. TD Cowen upgraded Royalty Pharma to a "strong-buy" rating in a research note on Tuesday, December 24th. Citigroup restated a "buy" rating on shares of Royalty Pharma in a research report on Friday. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $41.60.

Royalty Pharma Trading Down 1.7 %

RPRX traded down $0.55 during trading on Monday, reaching $30.82. 4,874,695 shares of the company's stock were exchanged, compared to its average volume of 4,455,436. The company's fifty day moving average price is $32.44 and its 200-day moving average price is $28.86. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The firm has a market capitalization of $17.77 billion, a PE ratio of 21.26, a P/E/G ratio of 2.31 and a beta of 0.47. Royalty Pharma plc has a fifty-two week low of $24.05 and a fifty-two week high of $34.20.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. As a group, equities analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 10th. Shareholders of record on Friday, February 21st were issued a $0.22 dividend. The ex-dividend date was Friday, February 21st. This is a positive change from Royalty Pharma's previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a yield of 2.86%. Royalty Pharma's dividend payout ratio (DPR) is 60.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.